Listen now
Key takeaways
- An SBOM is a formal, machine-readable inventory of all software components in a product, which has become a regulatory necessity for medical devices.
- The concern that an SBOM provides a 'playbook for attackers' is a misconception; a transparent and clean SBOM indicates a strong security posture, rather than a liability.
- Effective vulnerability prioritization should move beyond basic CVSS scores to focus on evidence of active exploitation, utilizing resources like the CISA KEV catalog and EPSS scores.
- Reachability analysis is a crucial method for vulnerability triage, as it determines if a vulnerable function within a third-party library is actually callable and used by the application's code.
- Unlike easily updated SaaS applications, patching medical devices in the field is logistically complex and expensive, making proactive security during development paramount.
- In addition to identifying security vulnerabilities, SBOMs are critical for managing open-source license compliance, especially with 'copyleft' licenses that can legally obligate a company to open-source its proprietary code.
- The FDA now requires SBOMs for medical devices, making their generation and analysis a necessary part of the regulatory process.
Why are Software Bill of Materials (SBOMs) critical for medical device security?
In this episode, Cortez Frazier Jr. joins Christian and Trevor to discuss SBOMs, vulnerability prioritization, and why companies should stop fearing software transparency. The conversation covers real-world security challenges, regulatory trends, and how organizations can protect themselves before a major breach forces them to act.
Cortez Frazier Jr. is a principal product manager at FOSSA, where he helps companies navigate software supply chain security with a mix of technical expertise and strategic foresight.
Key points:
-
Overview of FOSSA and its role in software composition analysis.
-
The increasing importance of SBOMs in regulatory compliance.
-
(10:30) Understanding SBOMs
-
How the SolarWinds attack changed the conversation around software transparency.
-
Why some manufacturers are reluctant to release SBOMs.
-
(20:45) Prioritizing Vulnerabilities
-
The difference between CVEs and actual exploitability risks.
-
Why blindly patching everything isn’t an effective security strategy.
-
(30:20) Legal and Compliance Risks
-
How open-source licenses can force companies to disclose their source code.
-
What manufacturers need to do to avoid unexpected legal issues.
-
(40:50) Future Trends
-
How hospitals and customers will soon start demanding SBOMs.
-
Cortez’s advice for companies looking to improve their cybersecurity posture.
Resources mentioned in this episode that you can Google:
-
Executive Order 14028.
-
SPDX and CycloneDX - Machine-readable SBOM formats
-
EPSS (Exploit Predictability Scoring System) - A better way to assess vulnerability risk
-
CISA Known Exploited Vulnerabilities List - The vulnerabilities that actually matter
Notable quotes
“I like to think about exploitable in a few orders of magnitude. The lowest fidelity is just a CVE in and of itself.”
“Cybersecurity 101 is you cannot defend or protect something that you don't know exists. And so getting an accurate and up-to-date inventory is always priority number one.”
“Often times we're relying on these third-party software, what they will call the software supply chain, if you will, and that is actually like a big area of risk. A lot of people were not actively paying attention to.”
Frequently asked questions
Bring this work to your device
Need help with fda premarket cybersecurity?
Blue Goat Cyber delivers fda premarket cybersecurity services for medical device manufacturers - from threat modeling to FDA-ready reports.
FDA Premarket Cybersecurity ServicesMore on FDA Premarket Cybersecurity
Keep listening
-
Episode 70
Why MedTech Needs Specialists with Zoltan Kevei and Saby Toth of Bishop & Co
With Zoltan Kevei
-
Episode 69
Science Before Hype in MedTech Investing with Varun Turlapati of Chaanakya Capital
With Varun Turlapati
-
Episode 67
De-Risking Product Decisions in MedTech Startups with Brent Lavin of Ironwood MedTech Partners
With Brent Lavin
-
Episode 65
Who Owns Patient Data Security in Trials with Rob Bedford, CEO of Franklyn Health
With Rob Bedford